MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
−Removed: Market Information
−Removed: Haemonetics' common stock is listed on the New York Stock Exchange ("NYSE") under the symbol HAE.
−Removed: There were 120 holders of record of the Company’s common stock as of March 28, 2020 .
−Removed: The Company has never paid cash dividends on shares of its common stock and does not expect to pay cash dividends in the foreseeable future.
Issuer Purchases of Equity Securities
−Removed: The following table provides information on the Company’s share repurchases during the fourth quarter of fiscal 2020:
−Removed: Number of Shares
−Removed: Average Price Paid per Share
−Removed: Total Number of Shares Purchased as Part of Publicly Announced Program
−Removed: Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (1)
−Removed: December 29, 2019 - January 25, 2020
−Removed: January 26, 2020 - February 22, 2020
−Removed: February 23, 2020 - March 28, 2020
−Removed: (1) In May 2019, the Company's Board of Directors authorized the repurchase of up to $500 million of the Company’s common stock from time to time, based on market conditions, over the next two years.
−Removed: Under the Company's share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Exchange Act, and in privately negotiated transactions.
−Removed: (2) In January 2020, the Company completed a $50.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement entered into with Bank of America, N.A.
−Removed: in December 2019.
−Removed: The total number of shares repurchased under the accelerated share repurchase agreement was 0.4 million at an average price per share upon final settlement of $114.73.
+Added: In May 2019, our Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the two year period ending May 2021.
+Added: We had no share repurchases during fiscal 2021.
+Added: The total remaining authorization for repurchases of our common stock under the share repurchase program was $325 million as of April 3, 2021.
+Added: We did not make any additional share repurchases under this program which expired in May 2021.
SELECTED FINANCIAL DATA
−Removed: Haemonetics Corporation Five-Year Review
−Removed: (In thousands, except per share and employee data)
−Removed: Summary of Operations:
−Removed: Cost of goods sold
−Removed: Operating expenses:
−Removed: Research and development
−Removed: Selling, general and administrative
−Removed: Impairment of assets
−Removed: Contingent consideration income
−Removed: Total operating expenses
−Removed: Operating income (loss)
−Removed: Gain on divestiture
−Removed: Interest and other expense, net
−Removed: Income (loss) before provision (benefit) for income taxes
−Removed: Provision (benefit) for income taxes
−Removed: Net income (loss)
−Removed: Income (loss) per share:
−Removed: Weighted average number of shares
−Removed: Weighted average number of shares and common stock equivalent shares
−Removed: Financial and Statistical Data:
−Removed: Working capital
−Removed: Current ratio
−Removed: Property, plant and equipment, net
−Removed: Capital expenditures
−Removed: Depreciation and amortization
−Removed: Stockholders’ equity
−Removed: Debt as a % of stockholders’ equity
+Added: This item is no longer required as we have elected to early adopt the changes to Item 301 of Regulation S-K contained in the Securities and Exchange Commission's Release No.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.